Future therapies in hormone-refractory prostate cancer

被引：26

作者：

Smith, MR

Nelson, JB

机构：

[1] Univ Pittsburgh, Med Ctr, Dept Urol, Pittsburgh, PA 15232 USA

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

来源：

UROLOGY | 2005年 / 65卷 / 5A期

关键词：

D O I：

10.1016/j.urology.2005.03.043

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Hormone-refractory prostate cancer (HRPC) remains true to its name: it is largely refractory to attempts to delay its progression. Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. To alter the currently inevitable progression of HRPC to death, new targets and new therapies are needed. This article reviews investigational therapies directed against standard targets (eg, the hypothalamic-pituitary-gonadal axis) as well as novel targets (eg, the endothelin axis).

引用

收藏

页码：9 / 16

页数：8

相关论文

共 72 条

[1] Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells [J].

Aalinkeel, R ;

Nair, MPN ;

Sufrin, G ;

Mahajan, SA ;

Chadha, KC ;

Chawda, RP ;

Schwartz, SA .

CANCER RESEARCH, 2004, 64 (15) :5311-5321

[2] IDENTITY OF THE 19S PROSOME PARTICLE WITH THE LARGE MULTIFUNCTIONAL PROTEASE COMPLEX OF MAMMALIAN-CELLS (THE PROTEASOME) [J].

ARRIGO, AP ;

TANAKA, K ;

GOLDBERG, AL ;

WELCH, WJ .

NATURE, 1988, 331 (6152) :192-194

[3] Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen [J].

Bander, NH ;

Trabulsi, EJ ;

Kostakoglu, L ;

Yao, D ;

Vallabhajosula, S ;

Smith-Jones, P ;

Joyce, MA ;

Milowsky, M ;

Nanus, DM ;

Goldsmith, SJ .

JOURNAL OF UROLOGY, 2003, 170 (05) :1717-1721

[4]

Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574

[5] Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent [J].

Bauer, KS ;

Dixon, SC ;

Figg, WD .

BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) :1827-1834

[6] Targeting FSH in androgen-independent prostate cancer: Abarelix for prostate cancer progressing after orchiectomy [J].

Beer, TM ;

Garzotto, M ;

Eilers, KM ;

Lemmon, D ;

Wersinger, EM .

UROLOGY, 2004, 63 (02) :342-347

[7] Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer [J].

Beer, TM ;

Eilers, KM ;

Garzotto, M ;

Egorin, MJ ;

Lowe, BA ;

Henner, WD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :123-128

[8] A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].

Bekker, PJ ;

Holloway, DL ;

Rasmussen, AS ;

Murphy, R ;

Martin, SW ;

Leese, PT ;

Holmes, GB ;

Dunstan, CR ;

DePaoli, AM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066

[9] Combined targeting of epidermal growth factor receptor and MDM2 by geritinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer [J].

Bianco, R ;

Caputo, R ;

Caputo, R ;

Damiano, V ;

De Placido, S ;

Ficorella, C ;

Agrawal, S ;

Bianco, AR ;

Ciardiello, F ;

Tortora, G .

CLINICAL CANCER RESEARCH, 2004, 10 (14) :4858-4864

[10] LOSS OF HLA CLASS-I EXPRESSION IN PROSTATE-CANCER - IMPLICATIONS FOR IMMUNOTHERAPY [J].

BLADES, RA ;

KEATING, PJ ;

MCWILLIAM, LJ ;

GEORGE, NJR ;

STERN, PL .

UROLOGY, 1995, 46 (05) :681-686

← 1 2 3 4 5 6 7 8 →